STOCK TITAN

United Therapeutics Corp - UTHR STOCK NEWS

Welcome to our dedicated news page for United Therapeutics (Ticker: UTHR), a resource for investors and traders seeking the latest updates and insights on United Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect United Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of United Therapeutics's position in the market.

Rhea-AI Summary
United Therapeutics Corporation (UTHR) announces President and COO's participation in the TD Cowen 44th Annual Health Care Conference. The company's focus on innovation for unmet medical needs and transplantable organs is highlighted.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.42%
Tags
conferences
-
Rhea-AI Summary
United Therapeutics Corporation (UTHR) reports record revenues of $2.33 billion for full year 2023, marking a 20% growth over 2022. The company achieved solid growth in its commercial business, particularly in the Tyvaso and Remodulin segments. Key financial highlights include a 25% increase in total revenues for the fourth quarter of 2023 compared to the same period in 2022. The company's innovative pipeline and organ manufacturing programs show promising growth potential.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.34%
Tags
earnings
-
Rhea-AI Summary
United Therapeutics Corporation initiates litigation against the FDA for allowing Liquidia Corporation to skirt FDA rules in seeking approval for a new drug indication. The lawsuit aims to protect United Therapeutics' patent rights and ensure fair FDA practices.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.34%
Tags
none
Rhea-AI Summary
United Therapeutics Corporation (UTHR) will announce its Q4 and full-year 2023 financial results on February 21, 2024. The company will host a webcast to discuss the results and highlight its commitment to innovation in the biotech and pharmaceutical sectors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.32%
Tags
conferences earnings
-
Rhea-AI Summary
United Therapeutics Corporation (Nasdaq: UTHR) announced that Dr. Martine Rothblatt, Chairperson and CEO, will provide an update on the company’s business at the 42nd Annual J.P. Morgan Healthcare Conference. The presentation will be available via live webcast and archived for 30 days. United Therapeutics is a public benefit corporation focused on developing novel pharmaceutical therapies and technologies to expand the availability of transplantable organs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.3%
Tags
conferences
-
Rhea-AI Summary
United Therapeutics Corporation (Nasdaq: UTHR) successfully completes the tender offer to acquire Miromatrix Medical Inc. (Nasdaq: MIRO) for $3.25 per share in cash at closing and an additional $1.75 per share in cash upon the achievement of a clinical development milestone related to mirokidney™ by December 31, 2025. 22,876,102 shares of Miromatrix common stock were validly tendered, representing approximately 83% of the issued and outstanding shares. Merger Sub merged with and into Miromatrix, making it a wholly owned subsidiary of United Therapeutics. Shares of Miromatrix common stock ceased trading on Nasdaq, and United Therapeutics intends to cause such shares to be delisted.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
acquisition
Rhea-AI Summary
United Therapeutics Corporation (Nasdaq: UTHR) successfully completes the tender offer to acquire Miromatrix Medical Inc. (Nasdaq: MIRO) for $3.25 per share in cash at closing and an additional $1.75 per share in cash upon the achievement of a clinical development milestone related to mirokidney™ by December 31, 2025. 22,876,102 shares of Miromatrix common stock were validly tendered, representing approximately 83% of the issued and outstanding shares. Merger Sub merged with and into Miromatrix, making it a wholly owned subsidiary of United Therapeutics. Shares of Miromatrix common stock ceased trading on Nasdaq, and United Therapeutics intends to cause such shares to be delisted.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.08%
Tags
acquisition
-
Rhea-AI Summary
United Therapeutics Corporation (Nasdaq: UTHR) and Miromatrix Medical Inc. (Nasdaq: MIRO) announced the results of the tender offer by Merger Sub, a United Therapeutics subsidiary, to acquire all outstanding shares of Miromatrix for $3.25 per share in cash at closing and an additional $1.75 per share in cash upon the achievement of a clinical development milestone related to Miromatrix’s mirokidney™ product by December 31, 2025. The tender offer expired with shares representing more than a majority of the issued and outstanding Miromatrix common stock validly tendered and received. The merger is expected to be completed on December 13, 2023, with Miromatrix becoming a wholly owned subsidiary of United Therapeutics and its shares delisted from Nasdaq.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.59%
Tags
none
-
Rhea-AI Summary
United Therapeutics Corporation (Nasdaq: UTHR) and Miromatrix Medical Inc. (Nasdaq: MIRO) announced the results of the tender offer by Merger Sub, a United Therapeutics subsidiary, to acquire all outstanding shares of Miromatrix for $3.25 per share in cash at closing and an additional $1.75 per share in cash upon the achievement of a clinical development milestone related to Miromatrix’s mirokidney™ product by December 31, 2025. The tender offer expired with shares representing more than a majority of the issued and outstanding Miromatrix common stock validly tendered and received. The merger is expected to be completed on December 13, 2023, with Miromatrix becoming a wholly owned subsidiary of United Therapeutics and its shares delisted from Nasdaq.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.79%
Tags
none
Rhea-AI Summary
United Therapeutics (Nasdaq: UTHR) has been named on Newsweek’s list of America’s Most Responsible Companies 2024. The company was recognized for its commitment to corporate social responsibility and sustainability, based on publicly available key performance indicators and an independent survey of U.S. residents.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.87%
Tags
none
United Therapeutics Corp

Nasdaq:UTHR

UTHR Rankings

UTHR Stock Data

10.91B
43.37M
1.72%
97.02%
2.46%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Silver Spring

About UTHR

united therapeutics corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions. we currently have five approved products on the market, and a long-term mission of providing an unlimited supply of transplantable organs for those who need them! our employees can be found collaborating across the united states, europe and asia. as a group, we are relentless in our pursuit of “medicines for life” and continue to research and develop treatments for cardiovascular and pulmonary diseases, pediatric cancers, and other orphan diseases. #weareunitherians